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Abstract
Background—Kidney function, expressed as glomerular filtration rate (GFR), is commonly 
estimated from serum creatinine (Scr) and, when decreased, may serve as a nonclassical risk factor 
for incident cardiovascular disease (CVD). The ability of estimated GFR (eGFR) to predict CVD 
events during 5–10 years of follow-up is assessed using data from the Strong Heart Study (SHS), a 
large cohort with a high prevalence of diabetes.
Methods—eGFRs were calculated with the abbreviated Modification of Diet in Renal Disease 
study (MDRD) and the Cockcroft-Gault (CG) equations. These estimates were compared in 
participants with normal and abnormal Scr. The association between eGFR and incident CVD was 
assessed.
Results—More subjects were labeled as having low eGFR (<60 ml/min per 1.73 m2) by the 
MDRD or CG equation, than by Scr alone. When Scr was in the normal range, both equations 
labeled similar numbers of participants as having low eGFRs, although concordance between the 
equations was poor. However, when Scr was elevated, the MDRD equation labeled more subjects 
as having low eGFR. Persons with low eGFR had increased risk of CVD.
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Conclusions—The MDRD and CG equations labeled more participants as having decreased 
GFR than did Scr alone. Decreased eGFR was predictive of CVD in this American Indian 
population with a high prevalence of obesity and type 2 diabetes mellitus.
Keywords
Cockcroft-Gault; Concordance; Cox proportional hazard model; Glomerular filtration rate; Kidney 
disease; MDRD; Serum creatinine
Introduction
Chronic kidney disease (CKD), even when glomerular filtration rate (GFR) is only mildly or 
moderately decreased, increases risk for all-cause and cardiovascular disease (CVD) 
mortality (1–5). Although an adverse CVD risk factor profile is associated with declining 
kidney function (6), CKD is independently associated with higher rates of CVD even after 
adjusting for CVD risk factors (7, 8), suggesting contributions from nonclassical CVD risk 
factors associated with decreased GFR. Accurate assessment of kidney function is, 
therefore, important for assessing cardiovascular risk. Normal GFR in adults aged 20–30 
years is approximately 125 ml/min per 1.73 m2 and declines each year by approximately 1 
ml/min per 1.73 m2 thereafter (9, 10). GFR is only rarely measured in clinical practice or in 
observational cohort studies, because of the technical challenges associated with infusion 
clearance techniques, resistance to the use of exogenous radiolabeled clearance markers and 
well-described inaccuracies in the collection of 24-hour urine samples. Absent these gold 
standard measures, GFR is usually estimated either by inspection of serum creatinine (Scr) 
values or, because of the insensitivity of Scr to early CKD (11), by the use of Scr-based 
estimating equations for GFR or creatinine clearance. These equations use Scr along with 
other demographic, clinical and laboratory data. While an emerging literature continues to 
explore alternative endogenous filtration markers which might improve the estimation of 
GFR, most strategies depend upon measurement of Scr, because it is easily, cheaply and 
reproducibly measured and serves as a relatively good filtration marker, due to proximal 
tubular secretion (12). These considerations led to the Kidney Disease Outcomes Quality 
Initiative (K/DOQI) guidelines, which recommend use of prediction equations, such as the 
Modification of Diet in Renal Disease (MDRD) study equation and the Cockcroft-Gault 
(CG) equation, to estimate GFR (13). These prediction formulae approximate unmeasured 
physiologic factors that affect serum creatinine level by using various demographic and 
clinical variables. Neither of these equations were developed in populations that included 
American Indians, and they have not been validated in an American Indian population (14).
In this article, we examine the concordance of estimated GFR (eGFR) measures as 
calculated with both the MDRD and the CG equations in a cohort characterized by high 
levels of obesity, diabetes and kidney abnormalities. We hypothesize low concordance 
between the MDRD and CG estimating equations among those with reduced kidney 
function as defined by Scr. These differences would depend on factors, such as age and sex. 
We used the MDRD equation to generate the thresholds for the normal and abnormal Scr 
groups. Therefore, we expect the MDRD eGFR to label subjects in concordance with their 
Scr levels.
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The Strong Heart Study (SHS) was initiated in 1988 to investigate CVD and its risk factors 
in geographically diverse groups of American Indians. The SHS design, survey methods and 
laboratory techniques have been published (15, 16). The SHS cohort of 4,549 American 
Indians includes men and women aged 45 to 74 years who were seen at the first examination 
(1989–1991). The second and third examinations were conducted in 1993–1995 and 1998–
2000, respectively. This population has a high prevalence of diabetes and kidney 
abnormalities (17, 18).
Clinical examination and laboratory determinations
Baseline and follow-up examinations consisted of a personal interview and a physical 
examination (15). Weight, height, blood pressure and waist and hip circumferences were 
measured (15, 16). Fasting blood samples were obtained for measures of lipids, insulin, 
plasma creatinine, plasma fibrinogen and glycated hemoglobin (A1c), and a 75-g oral 
glucose tolerance test was performed (19–24). Prevalent diabetes was identified by use of 
hypoglycemic agents, fasting glucose ≥126 mg/dL (25) or self-report.
Surveillance for cardiovascular events
CVD surveillance for nonfatal and fatal clinical events occurred throughout the follow-up 
period and is complete through December 31, 2002 (26). Criteria used to define definite 
fatal myocardial infarction (MI), stroke, coronary heart disease and nonfatal CVD have been 
published (27), as have methods for ascertaining incident CVD events (15, 28, 29).
Kidney function measures
Serum creatinine measures were performed by a single core laboratory and determined using 
automated alkaline picrate methodology run on a rapid flow analyzer (15, 28). We defined 
abnormal GFR as eGFR <60 ml/min per 1.73 m2 (30, 31). The SHS median age of 45 years 
and eGFR of 60 ml/min per 1.73 m2 were used to retrospectively define the corresponding 
Scr levels for the normal versus the abnormal groups. This definition estimates sex-specific 
thresholds of abnormal Scr (1.4 mg/dL in men and 1.1 mg/dL in women). Estimated GFR 
was calculated using 2 equations. The abbreviated MDRD equation is: 
, 
where Scr is measured in mg/dL and age in years (32).
Because SHS includes only American Indians, the MDRD equation factor for ethnicity was 
dropped for all participants. We note that other researchers have handled American Indian 
data similarly or have used a constant that was midway between those for whites and blacks 
(33). The CG equation to estimate creatinine clearance (CCr) is as follows:
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where age is measured in years, weight in kilograms and Scr in mg/dL (32). This result was 
then adjusted for body surface area (BSA) (34):
BSA was calculated as , where weight is measured in 
kilograms and height in centimeters.
Using the definitions and stages of kidney disease as defined by the US National Kidney 
Foundation, 4 groups were defined based on GFR as estimated by the MDRD and CG 
formulae: group 1 consisted of persons with normal eGFR as estimated by both the MDRD 
and the CG equations; group 2 consisted of persons defined as having normal eGFR by 
MDRD but abnormal eGFR by CG; group 3 consisted of persons having abnormal eGFR by 
MDRD and normal eGFR by CG; and group 4 consisted of persons defined as having 
abnormal eGFR as estimated by both MDRD and CG. Commentary is provided on results of 
supplementary analyses using the CG equation without normalization for body surface area.
Statistical analysis
Descriptive statistics of the subgroups are summarized with respect to age, sex, diabetes and 
CVD status. Mean Scr with corresponding 95% confidence intervals are presented. Mean 
eGFR was calculated using the 2 estimating equations, stratified by age categories and 
compared at baseline. Normal and abnormal kidney function groups were contrasted to 
study concordance between Scr and both of the GFR estimates and to study the 
characteristics of cases with abnormal kidney function that were not identified by Scr. The 
Cox proportional hazard model was used to determine the association between eGFR 
categories and CVD risk. A paired t-test was used to study mean differences among 
continuous GFR measures.
Results
Figure 1 shows the distribution of participants with complete data to allow calculation of 
GFR with the CG and MDRD equations. Figure 1 shows that 95.5% of the SHS subjects 
who had normal Scr levels also had normal eGFR using either estimating equation. 
Discordance between the 2 eGFR measures was present in groups 2 and 3, with 62 and 69 
subjects, respectively. In addition to the 131 subjects who showed at least 1 abnormal eGFR 
measure, 49 subjects were identified as having abnormal kidney function by both eGFR 
measures but not by Scr.
Table I shows selected baseline characteristics of the 4,011 participants with normal baseline 
Scr. As expected, mean Scr was lowest in group 1 and highest in group 4, with intermediate 
values in groups 2 and 3. Mean age followed a similar pattern. Those in group 3 were more 
likely to be female than those in group 2 (88.4% vs. 43.6%).
Of 347 subjects (Fig. 1) with abnormal baseline Scr, eGFR calculated with the CG formula 
indicated that 113 had normal kidney function, while the eGFR calculated with the MDRD 
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formula was, by design, consistent with the Scr results. Furthermore, analysis conducted 
using the CG equation without normalizing it to body surface area overestimated renal 
insufficiency, with 710 subjects labeled as having decreased estimated clearance (data not 
shown).
Tables II and III show diabetes-adjusted and multivariable-adjusted (with covariates for 
diabetes, age and sex) hazard ratios for the relationship between baseline eGFR and incident 
CVD over 5 and 10 years, respectively. Compared with participants whose eGFR was >90 
ml/min per 1.73 m2 at baseline, increased CVD risk was observed with reduced kidney 
function, even after adjustment for the effect of age, sex and diabetes. This relationship was 
observed for 5 and 10 years of follow-up with the same incremental increase in CVD risk 
with deteriorating kidney function.
Figure 2a, b shows mean eGFR by age and body mass index (BMI), respectively, as 
calculated by the equations (i) MDRD, (ii) CG and (iii) CG corrected for obesity (35). We 
adopted the Saracino correction (corrected CG = CG [1.25 - 0.012 BMI]) in part to account 
for some of the observed variability in the performance of the CG equation when estimating 
GFR, especially among obese subjects. Use of the Saracino correction decreased the 
divergence between MDRD and CG GFR estimates in subjects with BMI ≥30 and led to 
similar estimates for the slope of age-related GFR decline in our cohort.
Discussion
We compared 2 estimates of GFR in a population with a high prevalence of obesity and 
diabetes and at high risk for CKD and CVD. Among the 4,011 SHS participants with normal 
Scr, 4.5% had abnormal eGFR at baseline as assessed with either the MDRD or CG 
equations. Among persons with a normal Scr, the MDRD and CG equations identified about 
the same number of people with abnormal kidney function (n=111 for CG, vs. n=118 for 
MDRD), although only 49 individuals were common to both groups, suggesting poor 
concordance between these estimating equations.
Among the 347 individuals with an initially elevated Scr, nearly one third had normal 
kidney function (eGFR ≥60 ml/min per 1.73 m2) as estimated with the CG equation, but 
none had normal function as estimated with the MDRD equation. It is worth emphasizing 
that this inequality did not persist at later study visits. At the third SHS exam, 334 persons 
had abnormal Scr. Among those, 334 persons had abnormal eGFR as indicated by the 
MDRD equation, and all but 56 persons had abnormal eGFR as indicated by the CG 
equation (data not shown). Further, the age-stratified data showed that eGFR calculated with 
the MDRD and CG equations differed most in the youngest (aged 40–59 years) subjects and 
in those at extremes of BMI (<18.5 and >30). The improved agreement in eGFR between 
MDRD and the Saracino-corrected CG suggests that prevalent obesity in younger subjects 
may have significantly contributed to differences in eGFR.
Our major focus was on the ability of eGFR as calculated by MDRD and CG to predict new 
cases of CVD. Our data suggest that, compared with persons whose eGFR was ≥90 at 
baseline, those in the <30, 30–59 and 60–89 categories, using either estimating equation, had 
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increased risk of incident CVD. The risk increased as kidney function decreased. These 
findings were consistent in both adjusted and unadjusted analyses. When we conducted the 
same analyses using a dichotomy of eGFR ≥60 as the reference, where the 60–89 eGFR 
group was pooled with those with eGFR >90 (Tabs. II and III use >90 as the reference), we 
observed no association between eGFR <60 and incident CVD for either the MDRD or CG 
estimates. We suspect that this latter result is due both to misclassification of subjects with 
eGFR around 60 ml/min per 1.73 m2 and to our high-risk study population with its 
multiplicity of CVD risk factors as compared with most other white or multiethnic 
populations. Indeed, while Go et al (36) identified increased CVD as a function of eGFR 
with hazard ratios similar to ours, but with a reference of ≥60 ml/min per 1.73 m2 in the 
Kaiser Permanente Northern California registry, the effect of eGFR on CVD was only 
apparent in the National Health and Nutrition Examination Survey (37), the Atherosclerosis 
Risk in Communities study (38) and the Cardiovascular Health Study (39) using a reference 
eGFR of ≥ 90 ml/min per 1.73 m2.
Few epidemiologic studies include direct measures of GFR, because techniques such as 
kidney clearance of 125I-iothalamate are expensive and difficult to perform (40), thus, this 
and most other large studies of kidney disease depend on Scr and eGFR. The objective of 
this report was not to evaluate the performance of these measures with respect to a gold 
standard but to assess the concordance of these creatinine-based GFR estimating equations 
and their relative utility in identifying progressively decreased eGFR as a CVD risk factor. 
In this respect, when applied to our American Indian population, the MDRD and CG 
equations identified similar numbers of subjects as having CKD, although with poor 
agreement at an individual level. However, both measures identified progressive CKD as an 
independent predictor of incident CVD in this population with a high prevalence of obesity 
and diabetes. Whether better estimating equations, based on Scr, cystatin C or some other 
marker could be derived from specific validation studies in diverse groups of American 
Indians remains a subject for future investigation but should not impede further efforts to 
elucidate contributions of progressive CKD to cardiovascular morbidity and mortality in 
American Indians (33, 41, 42).
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Schematic of estimated glomerular filtration rate distribution stratified by normal versus 
abnormal serum creatinine (Scr) levels. CG = Cockcroft-Gault equation; MDRD = 
Modification of Diet in Renal Disease study equation.
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a) Mean estimated glomerular filtration rate (eGFR) at baseline calculated by the MDRD, 
CG and corrected CG, versus age category. b) Mean eGFR at baseline calculated by the 
MDRD, CG, and corrected CG, versus body mass index (BMI) category. CG = Cockcroft-
Gault equation; MDRD = Modification of Diet in Renal Disease study equation.
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TABLE II
COX PROPORTIONAL HAZARD MODELS SHOWING INCIDENCE OF CVD EVENTS IN SHS 5-
YEAR FOLLOW-UP, BY CATEGORY OF BASELINE KIDNEY FUNCTION
Reference: eGFR ≥90, 
number (event %)
eGFR 60–89, number (event 
%)
HR (95% CI)
eGFR 30–59, number (event %)
HR (95% CI)
eGFR <30, number (event %)
HR (95% CI)
Diabetes-adjusted analysis
MDRD 99 (7.94) 184 (8.88) 39 (13.13) 6 (14.63)
1.0 1.21 (0.95–1.54) 2.08 (1.44–3.10)* 4.10 (1.80–9.34)*
CG 161 (8.11) 136 (9.56) 25 (12.32) 5 (15.63)
1.0 1.35 (1.07–1.70)* 2.39 (1.57–3.64)* 4.39 (1.80–10.68)*
Multivariate adjusted analysis†
MDRD 99 (7.94) 184 (8.88) 39 (13.13) 6 (14.63)
1.0 1.20 (0.93–1.54) 1.94 (1.30–2.89)* 3.73 (1.63–8.53)*
CG 161 (8.11) 136 (9.56) 25 (12.32) 5 (15.63)
1.0 1.08 (0.84–1.40) 1.69 (1.06–2.71)* 3.67 (1.50–8.98)*
CG = Cockcroft-Gault equation; CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; HR = hazard ratio; MDRD = 
Modification of Diet in Renal Disease study equation; 95% CI = 95% confidence interval; SHS = Strong Heart Study.
*
Significant at the 5% level of significance.
†
Adjusted for diabetes, age and sex.
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TABLE III
COX PROPORTIONAL HAZARD MODELS SHOWING INCIDENCE OF CVD EVENTS IN SHS 10-
YEAR FOLLOW UP, BY CATEGORY OF BASELINE KIDNEY FUNCTION
eGFR ≥90, number 
(event %)
eGFR 60–89, number (event 
%)
HR (95% CI)
eGFR 30–59, number (event %)
HR (95% CI)
eGFR <30, number (event %)
HR (95% CI)
Diabetes-adjusted analysis
MDRD 268 (18.93) 464 (19.74) 122 (32.11) 24 (40.86)
1.0 1.12 (0.97–1.30) 2.08 (1.68–2.56)* 4.10 (2.70–6.22)*
CG 398 (17.91) 366 (22.14) 94 (34.56) 16 (37.21)
1.0 1.45 (1.26–1.67)* 2.89 (2.31–3.62)* 4.26 (2.58–7.02)*
Multivariate adjusted analysis†
MDRD 268 (18.93) 464 (19.74) 122 (32.11) 24 (40.86)
1.0 1.08 (0.93–1.26) 1.84 (1.47–2.32)* 3.87 (2.54–5.88)*
CG 398 (17.91) 366 (22.14) 94 (34.56) 16 (37.21)
1.0 1.12 (0.96–1.31) 2.01 (1.56–2.59)* 3.77 (2.29–6.23)*
CG = Cockcroft-Gault equation; CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; HR = hazard ratio; MDRD = 
Modification of Diet in Renal Disease study equation; 95% CI = 95% confidence interval; SHS = Strong Heart Study.
*
Significant at the 5% level of significance.
†
Adjusted for diabetes, age and sex.
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